Our services

Advance your compounds to the clinic with confidence

We are seasoned specialists in chronic pain and neurodegenerative disease drug discovery with a deep understanding for Client needs. We have a proven track record of developing customer-specific solutions for our Clients to ensure project progress.
Read more arrow_forward

We deliver high quality information

We’re not just providing data, we provide valuable information and clear answers to complex biological questions.

We accelerate your decision-making

Thanks to our highly experienced team, proprietary discovery platform and streamlined operations, we can shorten your project lead times.

Fast access to ground-breaking assays

We develop highly innovative in vitro assays based on complex biology that provide translationally relevant information.


An approach you can trust

We provide fully collaborative support, tailored to each individual study. Our Clients value our interactive and open communication style, our high capacity, quality and delivery precision needed for projects from target discovery and screening to lead optimization.

Read more

Our platform

Our unique discovery platform

Our team of highly experienced neurobiologists, stem cell researchers and engineers, has developed a unique and patent protected discovery platform which enables development of innovative in vitro assays of enhanced translational value.
Read more arrow_forward

News and events

Latest news and insights

Cellectricon values scientific exchange and we invite you to take part of our latest news, newsletters and to learn about upcoming events.

Read more

June 17, 2021
Webcast - The importance of non-neuronal cells in chronic pain – a Drug Discovery perspective
Event info: Pain drug discovery has historically been challenging with few new therapeutics reaching the market. In this webcast, Cellectricon...
Dr. Christian Vægter joins Cellectricon’s advisory board
Cellectricon has appointed Dr. Christian Vægter, Associate Professor and research group leader at Aarhus University, to its Scientific Advisory Board....
Cellectricon receives funding from Takeda’s open innovation platform
Cellectricon, a leading provider of neurobiology in vitro research services, is delighted to announce the initiation of a new research...
February 3, 2021
Webcast - New translational biomarkers and functional studies to support drug discovery and drug development for Alzheimer’s disease
Event info: In this three-part webcast, Professor Henrik Zetterberg first provided an overview presentation on recent developments in biomarker-supported drug...
November 19, 2020. 8 am PST / 11 am EST / 5 pm CET
Webinar - Discovery of NaV1.2 Modulators for Treating Autism Spectrum Disorder
Webinar description: Recent discoveries have shown that loss-of-function variants of SCN2A are causal for a number of neurodevelopmental disorders, including autism spectrum...
Dr. Franziska Denk joins Cellectricon’s advisory board
Cellectricon has appointed Dr. Franziska Denk, Lecturer at the Wolfson Centre for Age-Related Diseases, King’s College London, to its scientific...
June 25, 2020. 8 am PDT / 11 am EDT / 5 pm CEST
Webinar: Neuroinflammation in Chronic Pain – A Case for Interdisciplinary Research
Webinar Description: Neuroinflammation is a major feature of common nervous system disorders, including stroke, neurodegeneration, and chronic pain. And yet,...
Cellectricon’s new neuroinflammation discovery services offer advanced insight into chronic pain
Mölndal, Sweden Cellectricon, a collaborative services provider dedicated to advancing drug discovery and research in the areas of chronic pain...
Advancing pain research through scientific exchange
During the current COVID-19 pandemic many of our fellow researchers see disruption in their work and are prevented from sharing...

Get the latest news & events – sign up for our newsletter

Read about our Privacy Policy